Cullinan Therapeutics and Taiho Pharmaceutical Receive FDA Review for Cancer Therapy
Cullinan Therapeutics (CGEM) and Taiho Pharmaceutical have received FDA acceptance of a New Drug Application for zipalertinib, a cancer therapy. This development marks a significant step toward potential U.S. approval of the drug. The FDA's review could influence investor sentiment and stock performance for Cullinan Therapeutics.
Topics: cancer therapy Cullinan Therapeutics drug approval FDA Taiho Pharmaceutical zipalertinib